Moleculin Biotech, Inc.
Moleculin Biotech develops Annamycin, an anthracycline in Phase 2/3 development for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 17Latest story
November 2026
October 2026
September 2026
August 2026
July 2026
June 2026